A nanoemulsion vaccine for use in a method for preventing influenza virus infection in a subject, wherein the nanoemulsion vaccine comprises: (a) a nanoemulsion comprising: (i) droplets having an average diameter of less than 1000 nm; (ii) an aqueous phase; (iii) 1 % to 80% (v/v) soybean oil; (iv) 0.001% to 10% (v/v) of at least one surfactant, wherein the surfactant is Polysorbate 80, Polysorbate 20, or a combination thereof; (v) 0.1% to 50% (v/v) of at least one organic solvent, wherein the organic solvent is an alcohol; and; (vi) less than 5% (v/v) cetylpyridinium chloride; and (b) one or more influenza immunogens or recombinant influenza proteins from a virus strain selected from the group consisting of: an influenza A virus strain, or an immunogenic fragment of an influenza A virus strain; an influenza B virus strain or an immunogenic fragment of an influenza B virus strain; an influenza C virus strain or an immunogenic fragment of an influenza C virus strain; A/New Caledonia/20/99 lineage; A/Fujian/411/2002 lineage; A/Kumamoto/102/2002 lineage; A/Wyoming/3/2003 lineage; A/Wellington/1/2004 lineage; A/California/7/2004 lineage; A/New York/55/2004 lineage; A/Solomon Islands/3/2006 lineage; A/Wisconsin/67/2005 lineage; A/Hiroshima/52/2005 lineage; A/Brisbane/10/2007 lineage; B/Hong Kong/330/2001 lineage; B/Shandong/7/97 lineage; B/Hong Kong/1434/2002 lineage; S/Brisbane/32/2002 lineage; B/Shanghai/361/2002 lineage; B/Jiangsu/10/2003 lineage; B/Jilin/20/2003 lineage; B/Malaysia/2506/2004 lineage; B/Florida/4/2006 lineage, B/Victoria/2/87 lineage, B/Yamagata/16/88 lineage, C/Aichi/1/99 lineage, C/Sao Paulo/378/82 lineage, C/Yamagata/26/81 lineage, C/Aichi/1/81 lineage, C/Aomon/74 lineage, C/Mississippi/80 lineage, and any combination thereof, wherein the nanoemulsion vaccine is to be administered by a single intranasal administration to the subject (a) a nanoemulsion comprising: (i) droplets having an average diameter of less than 1000 nm; (ii) an aqueous phase; (iii) 1 % to 80% (v/v) soybean oil; (iv) 0.001% to 10% (v/v) of at least one surfactant, wherein the surfactant is Polysorbate 80, Polysorbate 20, or a combination thereof; (v) 0.1% to 50% (v/v) of at least one organic solvent, wherein the organic solvent is an alcohol; and; (vi) less than 5% (v/v) cetylpyridinium chloride; and (i) droplets having an average diameter of less than 1000 nm; (ii) an aqueous phase; (iii) 1 % to 80% (v/v) soybean oil; (iv) 0.001% to 10% (v/v) of at least one surfactant, wherein the surfactant is Polysorbate 80, Polysorbate 20, or a combination thereof; (v) 0.1% to 50% (v/v) of at least one organic solvent, wherein the organic solvent is an alcohol; and; (vi) less than 5% (v/v) cetylpyridinium chloride; and (b) one or more influenza immunogens or recombinant influenza proteins from a virus strain selected from the group consisting of: an influenza A virus strain, or an immunogenic fragment of an influenza A virus strain; an influenza B virus strain or an immunogenic fragment of an influenza B virus strain; an influenza C virus strain or an immunogenic fragment of an influenza C virus strain; A/New Caledonia/20/99 lineage; A/Fujian/411/2002 lineage; A/Kumamoto/102/2002 lineage; A/Wyoming/3/2003 lineage; A/Wellington/1/2004 lineage; A/California/7/2004 lineage; A/New York/55/2004 lineage; A/Solomon Islands/3/2006 lineage; A/Wisconsin/67/2005 lineage; A/Hiroshima/52/2005 lineage; A/Brisbane/10/2007 lineage; B/Hong Kong/330/2001 lineage; B/Shandong/7/97 lineage; B/Hong Kong/1434/2002 lineage; S/Brisbane/32/2002 lineage; B/Shanghai/361/2002 lineage; B/Jiangsu/10/2003 lineage; B/Jilin/20/2003 lineage; B/Malaysia/2506/2004 lineage; B/Florida/4/2006 lineage, B/Victoria/2/87 lineage, B/Yamagata/16/88 lineage, C/Aichi/1/99 lineage, C/Sao Paulo/378/82 lineage, C/Yamagata/26/81 lineage, C/Aichi/1/81 lineage, C/Aomon/74 lineage, C/Mississippi/80 lineage, and any combination thereof, an influenza A virus strain, or an immunogenic fragment of an influenza A virus strain; an influenza B virus strain or an immunogenic fragment of an influenza B virus strain; an influenza C virus strain or an immunogenic fragment of an influenza C virus strain; A/New Caledonia/20/99 lineage; A/Fujian/411/2002 lineage; A/Kumamoto/102/2002 lineage; A/Wyoming/3/2003 lineage; A/Wellington/1/2004 lineage; A/California/7/2004 lineage; A/New York/55/2004 lineage; A/Solomon Islands/3/2006 lineage; A/Wisconsin/67/2005 lineage; A/Hiroshima/52/2005 lineage; A/Brisbane/10/2007 lineage; B/Hong Kong/330/2001 lineage; B/Shandong/7/97 lineage; B/Hong Kong/1434/2002 lineage; S/Brisbane/32/2002 lineage; B/Shanghai/361/2002 lineage; B/Jiangsu/10/2003 lineage; B/Jilin/20/2003 lineage; B/Malaysia/2506/2004 lineage; B/Florida/4/2006 lineage, B/Victoria/2/87 lineage, B/Yamagata/16/88 lineage, C/Aichi/1/99 lineage, C/Sao Paulo/378/82 lineage, C/Yamagata/26/81 lineage, C/Aichi/1/81 lineage, C/Aomon/74 lineage, C/Mississippi/80 lineage, and any combination thereof,